bazedoxifene acetate

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2016
012320052016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Despite the capacity of estrogens to favorably regulate body composition and glucose homeostasis, their use to combat obesity and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
OBJECTIVE: Concerns of breast cancer risk in postmenopausal women taking combined estrogen + progestin therapy have generated… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2013
2013
OBJECTIVE The objectives of this study were to evaluate the effects of bazedoxifene acetate (BZA), a new selective estrogen… (More)
Is this relevant?
2012
2012
OBJECTIVE Concerns about increased breast cancer risk with estrogen and progestin therapy have led to an increased interest in… (More)
Is this relevant?
2011
2011
A Multidisciplinary National Panel of Experts in the management of Menopause and Postmenopausal Osteoporosis was created to… (More)
  • figure 1
Is this relevant?
2010
2010
Bazedoxifene acetate (BZA), a novel selective estrogen receptor modulator, is currently being developed for the prevention and… (More)
  • figure 1
  • figure 2
  • table 2
  • table 1
  • table 3
Is this relevant?
2008
2008
Selective estrogen receptor modulators (SERMs) have the unique potential to provide estrogenic effects in the skeletal and… (More)
Is this relevant?
Review
2008
Review
2008
  • Drugs in R&D
  • 2008
Bazedoxifene is a third-generation selective estrogen receptor modulator (SERM) that is being developed by Ligand Pharmaceuticals… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
We assessed the preclinical characteristics of a novel, stringently screened selective estrogen receptor modulator, bazedoxifene… (More)
Is this relevant?